Drug-induced long QT syndrome in women: Review of current evidence and remaining gaps

Gender Medicine

Volumn 5, Issue 2, 2008, Pages 124-135

  Hreiche, Raymond ^a   Morissette, Pierre ^a   Turgeon, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

drug induced long QT syndrome; gender; membrane transporters; metabolic enzymes; pharmacokinetics; sex; sexual hormones; torsades de pointes

Indexed keywords

AMIODARONE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BEPRIDIL; CISAPRIDE; CYTOCHROME P450; DISOPYRAMIDE; DROPERIDOL; ERYTHROMYCIN; ESTROGEN; HALOFANTRINE; IBUTILIDE; IMIDAZOLE DERIVATIVE; INTESTINE CONTRACTION STIMULATING AGENT; MACROLIDE; METHADONE; NEUROLEPTIC AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; PENTAMIDINE; PIMOZIDE; POTASSIUM CHANNEL HERG; QUINIDINE; SEX HORMONE; SILDENAFIL; SOTALOL; TERFENADINE; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE FAILURE; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE EXTRASYSTOLE; HORMONE DEPENDENCE; HUMAN; LONG QT SYNDROME; MEDLINE; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RECEPTOR BLOCKING; SEX DIFFERENCE; TORSADE DES POINTES;

ANIMALS; CAUSALITY; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GONADAL STEROID HORMONES; HUMANS; LONG QT SYNDROME; MEMBRANE TRANSPORT PROTEINS; POTASSIUM CHANNEL BLOCKERS; RISK FACTORS; SEX CHARACTERISTICS; SEX DISTRIBUTION; SEX FACTORS; TORSADES DE POINTES; WOMEN'S HEALTH;

EID: 45249083641     PISSN: 15508579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genm.2008.05.005     Document Type: Article

References (83)

1. Jervell A., and Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 54 (1957) 59-68
2. Romano C., Gemme G., and Pongiglione R. Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation (Presentation of 1st Case in Italian Pediatric Literature) [in Italian]. Clin Pediatr (Bologna) 45 (1963) 656-683
3. Ward O. A new familial cardiac syndrome in children. J Ir Med Assoc. 54 (1964) 103-106
4. Modell S., and Lehmann M. The long QT syndrome family of cardiac ion channelopathies: A HuGE review. Genet Med. 8 (2006) 143-155
5. Kääb S., Pfeufer A., Hinterseer M., et al. Long QT syndrome. Why does sex matter?. Z Kardiol. 93 (2004) 641-645
6. Locati E., Zareba W., Moss A., et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry. Circulation 97 (1998) 2237-2244
7. Selzer A., and Wray H. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964) 17-26
8. Roden D., Balser J., George Jr. A., and Anderson M. Cardiac ion channels. Annu Rev Physiol. 64 (2002) 431-475
9. Haverkamp W., Breithardt G., Camm A., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 47 (2000) 219-233
10. De Ponti F., Poluzzi E., and Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: A call for consensus. Eur J Clin Pharmacol. 57 (2001) 185-209
11. Morissette P., Hreiche R., and Turgeon J. Drug-induced long QT syndrome and torsade de pointes. Can J Cardiol. 21 (2005) 857-864
12. Arizona CERT. Drugs with a risk of torsades de pointes (April 30, 2008). http://www.qtdrugs.org/medical-pros/drug-lists/bycategory.cfm Accessed
13. Roden D. Drug-induced prolongation of the QT interval. N Engl J Med. 350 (2004) 1013-1022
14. Antzelevitch C., and Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 17 (2002) 43-51
15. Kannankeril P., and Roden D. Drug-induced long QT and torsade de pointes: Recent advances. Curr Opin Cardiol. 22 (2007) 39-43
16. Kr potassium channel. Cell 81 (1995) 299-307
17. Ks play a role in the reverse rate dependence of class III agents?. Circ Res. 78 (1996) 26-37
18. Li G., Feng J., Yue L., et al. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res. 78 (1996) 689-696
19. Yang T., Snyders D., and Roden D. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res. 80 (1997) 782-789
20. Numaguchi H., Johnson Jr. J., Petersen C., and Balser J. A sensitive mechanism for cation modulation of potassium current. Nat Neurosci. 3 (2000) 429-430
21. Kr. Implications for torsade de pointes and reverse use-dependence. Circulation 93 (1996) 407-411
22. Chakraborti S., Chakraborti T., Mandal M., et al. Protective role of magnesium in cardiovascular diseases: A review. Mol Cell Biochem. 238 (2002) 163-179
23. Roden D., and Anderson M. The pause that refreshes, or does it? Mechanisms in torsades de pointes. Heart 84 (2000) 235-237
24. Näbauer M., and Kääb S. Potassium channel downregulation in heart failure. Cardiovasc Res. 37 (1998) 324-334
25. Owens Jr. R. QT prolongation with antimicrobial agents: Understanding the significance. Drugs 64 (2004) 1091-1124
26. Daleau P., Lessard E., Groleau M., and Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 91 (1995) 3010-3016
27. Ray W., Murray K., Meredith S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 351 (2004) 1089-1096
28. Little R., Kay G., Cavender J., et al. Torsade de pointes and T-U wave alternans associated with arsenic poisoning. Pacing Clin Electrophysiol 13 (1990) 164-170
29. Ludomirsky A., Klein H., Sarelli P., et al. Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol. 49 (1982) 1654-1658
30. Di Pasquale G., Lusa A., Manini G., et al. Cardiac arrhythmias associated with subarachnoid hemorrhage. Prospective study with dynamic electrocardiography [in Italian]. G Ital Cardiol. 14 (1984) 323-329
31. Sen S., Stober T., Burger L., et al. Recurrent torsade de pointes type ventricular tachycardia in intracranial hemorrhage. Intensive Care Med. 10 (1984) 263-264
32. Roden D. Taking the 'idio" out of 'idiosyncratic": Predicting torsades de pointes. Pacing Clin Electrophysiol. 21 (1998) 1029-1034
33. Bazett H. An analysis of the time-relations of electrocardiograms. Heart 7 (1920) 353-370
34. Abinader E., and Shahar J. Possible female preponderance in prenylamine-induced 'torsade de pointes' tachycardia. Short communication. Cardiology 70 (1983) 37-40
35. Roden D., Woosley R., and Primm R. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J. 111 (1986) 1088-1093
36. Makkar R., Fromm B., Steinman R., et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270 (1993) 2590-2597
37. Woosley R., Chen Y., Freiman J., and Gillis R. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269 (1993) 1532-1536
38. Waldo A., Camm A., deRuyter H., et al., SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Survival With Oral d-Sotalol. [published correction appears in Lancet. 1996;348:416]. Lancet 348 (1996) 7-12
39. Drici M., Knollmann B., Wang W., and Woosley R. Cardiac actions of erythromycin: Influence of female sex. JAMA 280 (1998) 1774-1776
40. Gowda R., Khan I., Punukollu G., et al. Female preponderance in ibutilide-induced torsade de pointes. Int J Cardiol. 95 (2004) 219-222
41. Aytemir K., Maarouf N., Gallagher M., et al. Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol. 22 (1999) 1397-1401
42. Rautaharju P., Zhou S., Wong S., et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol. 8 (1992) 690-695
43. Morcet J., Safar M., Thomas F., et al. Associations between heart rate and other risk factors in a large French population. J Hypertens. 17 (1999) 1671-1676
44. Merri M., Benhorin J., Alberti M., et al. Electrocardiographic quantitation of ventricular repolarization. Circulation 80 (1989) 1301-1308
45. Kassotis J., Costeas C., Bedi A., et al. Effects of aging and gender on QT dispersion in an overtly healthy population. Pacing Clin Electrophysiol. 23 (2000) 1121-1126
46. Bidoggia H., Maciel J., Capalozza N., et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: Possible role of testosterone. Am Heart J. 140 (2000) 678-683
47. Stolt A., Karila T., Viitasalo M., et al. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol. 84 (1999) 364-366 A369
48. Larsen J., Tung R., Sadananda R., et al. Effects of hormone replacement therapy on QT interval. Am J Cardiol. 82 (1998) 993-995
49. Romhilt D., Chaffin C., Choi S., and Irby E. Arrhythmias on ambulatory electrocardiographic monitoring in women without apparent heart disease. Am J Cardiol. 54 (1984) 582-586
50. Rodriguez I., Kilborn M., Liu X., et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285 (2001) 1322-1326
51. Brouillette J., Trépanier-Boulay V., and Fiset C. Effect of androgen deficiency on mouse ventricular repolarization. J Physiol. 546 (2003) 403-413
52. Drici M., Burklow T., Haridasse V., et al. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 94 (1996) 1471-1474
53. Hara M., Danilo Jr. P., and Rosen M. Effects of gonadal steroids on ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther. 285 (1998) 1068-1072
54. Lu H., Remeysen P., Somers K., et al. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol. 12 (2001) 538-545
55. Liu X., Katchman A., Drici M., et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther. 285 (1998) 672-679
56. Trépanier-Boulay V., St-Michel C., Tremblay A., and Fiset C. Gender-based differences in cardiac repolarization in mouse ventricle. Circ Res. 89 (2001) 437-444
57. Arya A. Gender-related differences in ventricular repolarization: Beyond gonadal steroids. J Cardiovasc Electrophysiol. 16 (2005) 525-527
58. Pfeufer A., Jalilzadeh S., Perz S., et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: Results from the KORA study. Circ Res. 96 (2005) 693-701
59. Bezzina C., Verkerk A., Busjahn A., et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res. 59 (2003) 27-36
60. Pham T., and Rosen M. Sex, hormones, and repolarization. Cardiovasc Res. 53 (2002) 740-751
61. Almond L., Hoggard P., Edirisinghe D., et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother. 56 (2005) 738-744
62. Nelson D., Koymans L., Kamataki T., et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
63. Kolars J., Lown K., Schmiedlin-Ren P., et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 4 (1994) 247-259
64. Harris R., Benet L., and Schwartz J. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50 (1995) 222-239
65. Suzuki T., Zhao Y., Nadai M., et al. Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci. 79 (2006) 455-461
66. Ma J., Graves J., Bradbury J., et al. Regulation of mouse renal CYP2J5 expression by sex hormones. Mol Pharmacol. 65 (2004) 730-743
67. Wang J., Yang Y., Sullivan M., et al. Induction of cardiac cytochrome p450 in cocaine-treated mice. Exp Biol Med (Maywood). 227 (2002) 182-188
68. Zordoky B., and El-Kadi A. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab. 9 (2008) 122-128
69. Thum T., and Borlak J. Gene expression in distinct regions of the heart. Lancet 355 (2000) 979-983
70. Walles M., Thum T., Levsen K., and Borlak J. Verapamil: New insight into the molecular mechanism of drug oxidation in the human heart. J Chromatogr A. 970 (2002) 117-130
71. Silverman J. Multidrug-resistance transporters. In: Amidon G., and Sadée W. (Eds). Membrane Transporters As Drug Targets (1999), Kluwer Academic/Plenum Publishers, New York, NY 353-387
72. Meissner K., Jedlitschky G., Meyer zu Schwabedissen H., et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14 (2004) 381-385
73. Couture L., Nash J., and Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: A special look at the heart. Pharmacol Rev. 58 (2006) 244-258
74. Morris M., Lee H., and Predko L. Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev. 55 (2003) 229-240
75. Schuetz E., Furuya K., and Schuetz J. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 275 (1995) 1011-1018
76. Dagenais C., Zong J., Ducharme J., and Pollack G. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res. 18 (2001) 957-963
77. Hagenbuch B., and Meier P. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 1609 (2003) 1-18
78. Kobayashi Y., Hirokawa N., Ohshiro N., et al. Differential gene expression of organic anion transporters in male and female rats. Biochem Biophys Res Commun. 290 (2002) 482-487
79. Buist S., Cherrington N., Choudhuri S., et al. Gender-specific and developmental influences on the expression of rat organic anion transporters. J Pharmacol Exp Ther. 301 (2002) 145-151
80. Grube M., Meyer zu Schwabedissen H., Prager D., et al. Uptake of cardiovascular drugs into the human heart: Expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 113 (2006) 1114-1122
81. Oswald S., Grube M., Siegmund W., and Kroemer H. Transporter-mediated uptake into cellular compartments. Xenobiotica 37 (2007) 1171-1195
82. Michaud V., Masse R., and Turgeon J. CYP2J2 metabolizes domperidone in guinea pig hearts. Clin Pharmacol Ther. 77 (2005) 75
83. Morissette P., Hreiche R., and Turgeon J. Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride. Can J Physiol Pharmacol. 84 (2006) 1285-1290